World Journal of Pharmaceutical and Life Sciences
WJPLS
www.wjpls.org
SJIF Impact Factor: 6.129

INVITRO EVALUATION OF GEMCITABINE AND ITS DERIVATIVE (GEMCITABINE-ERLOTINIB) FOR THE TREATMENT OF PANCREATIC CANCER

Dr. Syed Ahmed Hussain*[1], Shaik Nazma Sultana[1], Sara Umm E. Hani[1], Farahanaaz Begum[1] and Juveria Gaffar[1]

[1]Department of Pharmacology, Shadan Women's College of Pharmacy, Hyderabad.

***Corresponding Author: Dr. Syed Ahmed Hussain**
Department of Pharmacology, Shadan Women's College of Pharmacy, Hyderabad.

Article Received on 19/10/2023 **Article Revised on 08/11/2023** **Article Accepted on 29/11/2023**

ABSTRACT

This research paper examines the cellular impact of Gemcitabine-Erlotinib combination therapy on viability, tubulogenesis, and protein expression levels using MTT assay, Tubulogenesis assay, Indirect Immunofluorescence assay, and Western Blot analysis. The study encompasses four treatment groups: Group 1 (normal), Group 2 (Control cell line), Group 3 (Standard GEMCITABINE), and Group 4 (Gemcitabine-Erlotinib). The results suggest that Gemcitabine-Erlotinib has a significant effect on cell viability and tubulogenesis, while also affecting protein expression levels. These findings emphasize the potential impact of this combination therapy on cellular processes and warrant further investigation.

1. INTRODUCTION

Cell viability refers to the ability of a cell to stay alive and function properly. It is a critical aspect of cellular health and is often used as an indicator of the overall well-being of cells in various biological and biomedical contexts. Understanding and assessing cell viability is fundamental in fields such as cell biology, microbiology, tissue engineering, drug development, and toxicology, among others.

Several factors can influence cell viability, including

1. **Nutrient Availability:** Cells require nutrients like glucose, amino acids, vitamins, and minerals to sustain their metabolic activities. A lack of essential nutrients can lead to decreased cell viability.
2. **Oxygen Supply:** Aerobic organisms, including most human cells, require oxygen for cellular respiration. Hypoxia, or a lack of oxygen, can significantly impact cell viability.
3. **pH Levels:** Cells maintain a specific intracellular pH, and any significant deviation from this range can harm cell viability. Both acidic and alkaline conditions can be detrimental.
4. **Temperature:** Cells have an optimal temperature range in which they function best. Extreme temperatures can disrupt cell membranes, proteins, and other cellular structures, leading to cell death.
5. **Toxic Substances:** Exposure to toxic chemicals, drugs, or environmental pollutants can negatively affect cell viability. Toxic substances can disrupt cellular processes and induce cell death.
6. **Radiation:** Ionizing radiation, such as X-rays and gamma rays, can damage cellular DNA and other structures, leading to decreased cell viability.

Cell viability is often assessed through various methods, including:

1. **Trypan Blue Exclusion:** This dye is used to distinguish between live and dead cells. Live cells exclude the dye, while dead cells take up the dye and become stained.
2. **MTT Assay:** This colorimetric assay measures the activity of mitochondrial enzymes in live cells. Live cells convert a yellow MTT reagent into a purple formazan product.
3. **Cell Counting:** The total number of live and dead cells in a sample can be determined using a hemocytometer or automated cell counter.
4. **Flow Cytometry:** This technique allows for the analysis of individual cells within a population based on various parameters, including cell viability markers.
5. **Fluorescent Staining:** Fluorescent dyes such as propidium iodide and calcein-AM can be used to assess cell viability by distinguishing between live and dead cells under a microscope or using flow cytometry.
6. **ATP Assays:** Adenosine triphosphate (ATP) is a molecule produced in live cells, so ATP assays can be used to measure cell viability indirectly.

The assessment of cell viability is crucial in various scientific and clinical applications. In medical research, it is used to evaluate the effects of drugs, toxins, and disease on cell health. In tissue engineering, it helps monitor the success of growing and maintaining cell cultures. In the pharmaceutical industry, it is essential for drug development and testing. Overall, understanding and maintaining cell viability is critical for advancing our knowledge of biology and for improving health and biotechnological processes.

Cell viability and cell toxicity are related concepts that are often used to assess the health and condition of cells, but they represent different aspects of cellular well-being:

1. **Cell Viability**

- **Definition:** Cell viability refers to the ability of cells to remain alive and maintain their normal physiological functions.
- **Indication:** It is a measure of whether a cell is alive or dead. A viable cell is one that is functioning properly and capable of carrying out its usual cellular processes.
- **Methods of Assessment:** Cell viability is typically assessed using various methods like dye exclusion assays (e.g., trypan blue exclusion), metabolic activity assays (e.g., MTT assay), and monitoring cellular ATP levels. These methods determine the proportion of living cells within a population.
- **Applications:** Cell viability is important in various fields such as cell biology, tissue engineering, drug development, and microbiology. Researchers use it to evaluate the overall health and functionality of cells.

Combination therapies in cancer treatment have become increasingly important in improving patient outcomes. This study focuses on the combination of Gemcitabine and Erlotinib, aiming to assess its effects on cellular viability, tubulogenesis, and protein expression levels. The need to understand the cellular impact of this combination therapy is critical to optimize its clinical application.

2. RESEARCH METHODOLOGY

2.1. MTT Assay Cellular viability was assessed using the MTT assay, with four treatment groups: Group 1 (normal), Group 2 (Control cell line), Group 3 (Standard GEMCITABINE), and Group 4 (Gemcitabine-Erlotinib). Cellular viability was quantified by measuring absorbance, with lower absorbance values indicating decreased cellular viability.

2.2. Tubulogenesis Assay The Tubulogenesis assay investigated the impact of Gemcitabine-Erlotinib on cellular tubulogenesis. The same four treatment groups were used. This assay examined the ability of cells to form tubular structures.

2.3. Indirect Immunofluorescence Assay The Indirect Immunofluorescence assay was employed to examine changes in protein localization patterns due to Gemcitabine-Erlotinib treatment. All four treatment groups (Group 1, Group 2, Group 3, and Group 4) were analyzed to determine alterations in protein distribution within cells.

2.4. Western Blot Analysis Protein expression levels were assessed using Western Blot analysis. The four groups, Group 1 (normal), Group 2 (Control cell line), Group 3 (Standard GEMCITABINE), and Group 4 (Gemcitabine-Erlotinib), were examined for differences in protein expression levels.

RESULTS of Gemcitabine-erlotinib
MTT Assay

Treatments	MTT Assay
Group 1 (normal)	89.26
Group 2 (Control cell line)	93.18
Group 3 (Standard) GEMCITABINE	66.42
Group 4 (Gemcitabine-erlotinib)	66.32



Tubulogenesis Assay

Treatments	Tubulogenesis Assay
Group 1 (normal)	77.18
Group 2 (Control cell line)	89.43
Group 3 (Standard) GEMCITABINE	47.24
Group 4 (Gemcitabine-erlotinib)	37.26



Indirect Immunofluorescence Assay

Treatments	Indirect Immunofluorescence Assay
Group 1 (normal)	87.43
Group 2 (Control cell line)	98.18
Group 3 (Standard) GEMCITABINE	65.13
Group 4 (Gemcitabine-erlotinib)	59.16



Western Blot Analysis

Treatments	Western Blot Analysis
Group 1 (normal)	1.54
Group 2 (Control cell line)	1.96
Group 3 (Standard) GEMCITABINE	0.47
Group 4 (Gemcitabine-erlotinib)	0.42



3. DISCUSSION

3.1. MTT Assay The MTT assay results show a minor decrease in cellular viability in Group 4 (Gemcitabine-Erlotinib) compared to Group 3 (Standard GEMCITABINE). This suggests that Gemcitabine-Erlotinib has a limited effect on cellular viability. Further studies may be required to investigate its potential advantages.

3.2. Tubulogenesis Assay In the Tubulogenesis assay, Group 4 (Gemcitabine-Erlotinib) demonstrated a decrease in the formation of tubular structures compared to the control groups (Group 1 and Group 2). This indicates that Gemcitabine-Erlotinib may inhibit

tubulogenesis, which may have implications for certain physiological processes. Additional research is needed to understand these implications.

3.3. Indirect Immunofluorescence Assay The Indirect Immunofluorescence assay showed changes in protein localization patterns in Group 4 (Gemcitabine-Erlotinib), suggesting potential disruptions in cellular processes. The mechanisms behind these changes should be investigated to understand the impact of Gemcitabine-Erlotinib on protein expression.

3.4. Western Blot Analysis Group 4 (Gemcitabine-Erlotinib) exhibited alterations in protein expression levels, which were slightly lower than Group 3 (Standard GEMCITABINE). These variations may impact cell function, and further research is needed to identify the specific proteins affected.

4. CONCLUSION

The results of this study suggest that Gemcitabine-Erlotinib has a minor effect on cellular viability and may inhibit tubulogenesis compared to standard Gemcitabine treatment. Additionally, this combination therapy may impact protein expression levels. While these effects are relatively modest, they indicate potential interactions that may be of clinical significance. Further research is needed to fully understand the mechanisms and clinical implications of Gemcitabine-Erlotinib combination therapy in cancer treatment.

BIBLIOGRAPHY

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. *CA Cancer J Clin.,* Mar–Apr, 2008; 58(2): 71–96.
2. ACS. *Cancer Facts & Figures 2008.* Atlanta: American Cancer Society, 2008.
3. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. *Gut.,* Mar., 2005; 54(3): 385–7.
4. Jamieson JD. Prospectives for cell and organ culture systems in the study of pancreatic carcinoma. *J Surg Oncol.,* 1975; 7(2): 139–41.
5. Longnecker DS, Wiebkin P, Schaeffer BK, Roebuck BD. Experimental carcinogenesis in the pancreas. *Int Rev Exp Pathol.,* 1984; 26: 177–229.
6. Hall PA, Lemoine NR. Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas. *J Pathol.,* Feb., 1992; 166(2): 97–103.
7. Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. *Proc Natl Acad Sci U S A.,* Dec 2, 2008; 105(48): 18913–8.
8. Park SW, Davison JM, Rhee J, Hruban RH, Maitra A, Leach SD. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. *Gastroenterology,* Jun., 2008; 134(7): 2080–90.
9. Murtaugh LC, Leach SD. A case of mistaken identity? Nonductal origins of pancreatic “ductal” cancers. *Cancer Cell.,* Mar., 2007; 11(3): 211–3.
10. Githens S. Pancreatic duct cell cultures. *Annu Rev Physiol.,* 1994; 56: 419–43.
11. Githens S. The pancreatic duct cell: proliferative capabilities, specific characteristics, metaplasia, isolation, and culture. *J Pediatr Gastroenterol Nutr.,* Jul–Aug, 1988; 7(4): 486–506.
12. Bonner-Weir S, Toschi E, Inada A, Reitz P, Fonseca SY, Aye T, et al. The pancreatic ductal epithelium serves as a potential pool of progenitor cells. *Pediatric diabetes,* 2004; 5(2): 16–22.
13. Jones RT, Barrett LA, van Haaften C, Harris CC, Trump BF. Carcinogenesis in the pancreas. I. Long-term explant culture of human and bovine pancreatic ducts. *J Natl Cancer Inst.,* Mar., 1977; 58(3): 557–65.
14. Oda D, Savard CE, Nguyen TD, Swenson ER, Lee SP. Culture of human main pancreatic duct epithelial cells. *In Vitro Cell Dev Biol Anim.,* Mar., 1998; 34(3): 211–6.
15. Trautmann B, Schlitt HJ, Hahn EG, Lohr M. Isolation, culture, and characterization of human pancreatic duct cells. *Pancreas,* Mar., 1993; 8(2): 248–54.
16. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. *Am J Pathol,* Jun., 1996; 148(6): 1763–70.
17. Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. *Am J Pathol,* Nov., 2000; 157(5): 1623–31.
18. Lee KM, Yasuda H, Hollingsworth MA, Ouellette MM. Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. *Lab Invest.,* Aug., 2005; 85(8): 1003–12.
19. Qian J, Niu J, Li M, Chiao PJ, Tsao MS. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. *Cancer Res.,* Jun 15, 2005; 65(12): 5045–53.
20. Campbell PM, Lee KM, Ouellette MM, Kim HJ, Groehler AL, Khazak V, et al. Ras-driven transformation of human nestin-positive pancreatic epithelial cells. *Methods Enzymol.,* 2008; 439: 451–65.
21. Bendayan M, Duhr MA, Gingras D. Studies on pancreatic acinar cells in tissue culture: basal lamina (basement membrane matrix promotes three-

dimensional reorganization. *Eur J Cell Biol.,* Oct, 1986; 42(1): 60–7.
22. Longnecker DS, Lilja HS, French J, Kuhlmann E, Noll W. Transplantation of azaserine-induced carcinomas of pancreas in rats. *Cancer Lett.,* Aug, 1979; 7(4): 197–202.
23. Ulrich AB, Schmied BM, Standop J, Schneider MB, Pour PM. Pancreatic cell lines: a review. *Pancreas,* Mar, 2002; 24(2): 111–20.
24. Esni F, Miyamoto Y, Leach SD, Ghosh B. Primary explant cultures of adult and embryonic pancreas. *Methods Mol Med.,* 2005; 103: 259–71.
25. Hober C, Benhamou PY, Watt PC, Watanabe Y, Nomura Y, Stein E, et al. A new culture method for human pancreatic islets using a biopore membrane insert. *Pancreas,* Mar, 1997; 14(2): 199–204.